- Home
- CRBP vs SOL Comparison
CRBP vs SOL Comparison
Compare CRBP & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBP
- SOL
- Stock Information
- Founded
- CRBP 2009
- SOL 2005
- Country
- CRBP United States
- SOL United States
- Employees
- CRBP N/A
- SOL N/A
- Industry
- CRBP Biotechnology: Pharmaceutical Preparations
- SOL Semiconductors
- Sector
- CRBP Health Care
- SOL Technology
- Exchange
- CRBP Nasdaq
- SOL Nasdaq
- Market Cap
- CRBP 73.4M
- SOL 84.6M
- IPO Year
- CRBP N/A
- SOL 2008
- Fundamental
- Price
- CRBP $7.34
- SOL $1.66
- Analyst Decision
- CRBP Strong Buy
- SOL Buy
- Analyst Count
- CRBP 10
- SOL 3
- Target Price
- CRBP $53.56
- SOL $3.50
- AVG Volume (30 Days)
- CRBP 114.6K
- SOL 145.9K
- Earning Date
- CRBP 05-06-2025
- SOL 05-14-2025
- Dividend Yield
- CRBP N/A
- SOL N/A
- EPS Growth
- CRBP N/A
- SOL N/A
- EPS
- CRBP N/A
- SOL N/A
- Revenue
- CRBP N/A
- SOL $85,621,000.00
- Revenue This Year
- CRBP N/A
- SOL N/A
- Revenue Next Year
- CRBP $150.00
- SOL $45.37
- P/E Ratio
- CRBP N/A
- SOL N/A
- Revenue Growth
- CRBP N/A
- SOL N/A
- 52 Week Low
- CRBP $4.64
- SOL $1.04
- 52 Week High
- CRBP $61.90
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- CRBP 52.51
- SOL 55.23
- Support Level
- CRBP $7.05
- SOL $1.63
- Resistance Level
- CRBP $7.62
- SOL $1.87
- Average True Range (ATR)
- CRBP 0.49
- SOL 0.12
- MACD
- CRBP -0.02
- SOL 0.02
- Stochastic Oscillator
- CRBP 42.65
- SOL 46.15
About CRBP Corbus Pharmaceuticals Holdings Inc.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.